Endobronchial Ultrasound Biopsy Market Set to Reach $1.28 Billion by 2033

Global Endobronchial Ultrasound Biopsy Market Overview

According to Renub Research Latest Report endobronchial ultrasound (EBUS) biopsy market is projected to grow from USD 820 million in 2024 to USD 1,275.36 million by 2033, expanding at a CAGR of 5.03% during the forecast period. The market’s growth is primarily fueled by the increasing incidence of lung cancer and other respiratory diseases, the rise in demand for minimally invasive diagnostic procedures, and technological advancements in ultrasound imaging and biopsy tools.

EBUS is a minimally invasive diagnostic technique that combines endoscopy with ultrasound to accurately sample lung tissue and lymph nodes. It offers a safer, faster, and more precise alternative to traditional surgical biopsies, reducing patient recovery times and procedural risks. With its ability to reach hard-to-access lesions, EBUS has become crucial for non-small cell lung cancer (NSCLC) staging, infection diagnosis, and other thoracic conditions.

Leading market players, including Cook Medical, Boston Scientific, Medtronic, Olympus Corporation, GE Healthcare, Siemens Healthcare, FUJIFILM, and Philips, are actively developing new EBUS systems, needles, and imaging technologies to meet rising clinical demand.

👉 Want to explore detailed market trends, segment insights, and forecasts? 🔗 Request Sample Report

Market Growth Drivers

Rising Incidence of Lung Cancer

Lung cancer continues to be a leading cause of cancer-related deaths worldwide, especially NSCLC. Early diagnosis and accurate staging are critical for improving survival rates, and EBUS-guided biopsies have become an essential diagnostic tool.

According to the American Cancer Society, approximately 226,650 new lung cancer cases are expected in the U.S. in 2025, with roughly 124,730 associated fatalities. As lung cancer incidence rises globally due to smoking, air pollution, and occupational hazards, the need for minimally invasive and precise diagnostic tools like EBUS grows correspondingly.

Shift Toward Minimally Invasive Procedures

Healthcare providers increasingly prefer less invasive procedures to reduce patient discomfort, hospitalization time, and medical costs. Traditional surgical biopsies carry risks of infection, longer recovery periods, and higher procedural costs.

EBUS offers real-time imaging guidance for precise tissue sampling, allowing physicians to diagnose and stage lung lesions safely. Its minimally invasive nature and improved safety profile make it the preferred choice in modern pulmonary diagnostics, fueling adoption in hospitals, specialty clinics, and ambulatory surgical centers worldwide.

Technological Advancements in EBUS Systems

Continuous innovation in EBUS technology is a major driver of market growth. Advancements include:

High-resolution imaging systems for enhanced visualization of lesions and lymph nodes.

Real-time needle guidance for accurate tissue sampling.

Integration with linear and radial bronchoscopes to access peripheral lesions.

For example, in September 2024, FUJIFILM Healthcare Europe GmbH launched the ARIETTA 750 FF ENDO ultrasound system, which supports linear bronchoscopes and multiple endoscopes. Features such as Carving Imaging and eFocusing improve visualization and diagnostic accuracy, making EBUS procedures more effective.

Growing Adoption in Emerging Markets

The EBUS biopsy market is expanding in emerging regions due to improvements in healthcare infrastructure, increased awareness of lung diseases, and greater accessibility to advanced diagnostic equipment. Government initiatives and healthcare investments in developing nations facilitate adoption, particularly in Asia-Pacific and Latin America.

Hospitals and diagnostic centers in these regions are increasingly equipping themselves with modern EBUS systems, promoting early detection of lung cancer and other pulmonary disorders. Rising patient awareness and physician preference for minimally invasive diagnostics are further supporting market growth.

Market Challenges

High Equipment Costs

The initial acquisition and maintenance costs of EBUS systems are high. In addition to the primary equipment, healthcare facilities must invest in specialized probes, imaging accessories, and regular maintenance. Training staff to operate these systems efficiently adds to operational expenses.

As a result, EBUS adoption is often limited to larger hospitals and well-funded specialty centers, especially in regions with budget constraints. Smaller clinics may struggle to justify the cost, slowing broader market penetration.

Limited Availability of Trained Personnel

Effective EBUS procedures require skilled pulmonologists and technicians trained in real-time imaging interpretation and precise tissue sampling. A shortage of such professionals, especially in rural areas and developing countries, can impede adoption.

Operator skill is critical for accurate diagnosis and staging. Inadequate training may lead to inconsistent results, delayed treatment, and reduced patient outcomes, posing a significant challenge to market expansion.

Regional Market Insights

United States

The U.S. holds a dominant share of the global EBUS market, driven by:

Rising incidence of lung cancer and other pulmonary disorders.

Adoption of minimally invasive diagnostic techniques in hospitals and specialty clinics.

Robust healthcare infrastructure, high R&D investments, and regulatory support for advanced medical devices.

In 2024, the American Cancer Society projected 2 million new cancer cases in the U.S., with lung and bronchus cancer accounting for approximately 234,500 cases. The increasing number of patients requiring early diagnosis and minimally invasive biopsy procedures is expected to drive EBUS market growth in the country.

United Kingdom

EBUS adoption in the UK is expanding due to technological advancements in diagnostics and the need for less invasive procedures. Government support for healthcare innovation and reimbursement schemes encourages hospitals to integrate EBUS systems.

However, high equipment costs and the need for trained personnel may limit full adoption in some areas, though overall growth is projected to remain steady.

India

India’s EBUS market is growing rapidly, supported by expanding healthcare infrastructure, rising awareness of lung diseases, and government programs aimed at improving diagnostic capabilities. Hospitals and specialty clinics increasingly employ EBUS for early detection of lung cancer, TB, and other respiratory disorders.

Challenges include equipment affordability and lack of specialized training, which could affect adoption rates in smaller healthcare centers.

Saudi Arabia

In Saudi Arabia, the EBUS market is expanding with investments in modern healthcare facilities and minimally invasive diagnostic technologies. Increasing awareness of lung cancer and respiratory disorders, coupled with government initiatives to improve healthcare quality, supports adoption. High equipment costs and limited trained staff remain potential challenges.

👉 For deeper analysis, detailed segment data, and company insights: 🔗 Request Customization Report

Product Segmentation

EBUS Scopes: Essential for endoscopic visualization and lesion access.

EBUS Needles: Enable precise tissue sampling for diagnosis and staging.

Ultrasound Processors & Imaging Systems: Enhance image clarity and diagnostic accuracy.

Accessories: Include biopsy kits, guide sheaths, and other supporting tools.

Application Segmentation

Cancer Diagnostics: Primary driver of EBUS adoption, particularly for NSCLC staging.

Infection Diagnostics: Includes TB and other pulmonary infections.

Others: Covers research applications and rare pulmonary conditions.

End-Use Segmentation

Hospitals: Largest segment due to high patient volume and advanced infrastructure.

Ambulatory Surgical Centers (ASCs): Growing adoption for outpatient diagnostic procedures.

Specialty Clinics: Increasing use in pulmonology and oncology centers.

Recent Developments

GE Healthcare announced in October 2024 the expansion of its medical imaging manufacturing in Waukesha County, Wisconsin, to meet growing global demand.

Praxis’ EndoCore EBUS-TBNA system received FDA approval in October 2023, enhancing biopsy accuracy and patient outcomes.

FUJIFILM’s ARIETTA 750 FF ENDO ultrasound system integrates advanced imaging features with multiple endoscope compatibility, improving diagnostic precision.

Key Market Players

GE Healthcare – Expanding imaging and EBUS product lines globally.

Siemens Healthcare – Offering high-end ultrasound systems for pulmonary diagnostics.

Koninklijke Philips N.V. – Innovating in minimally invasive imaging and biopsy solutions.

Boston Scientific Corporation – Specializes in EBUS scopes, needles, and accessories.

Olympus Corporation – Leader in endoscopic and ultrasound diagnostic tools.

Cook Group Incorporated – Focused on needle and biopsy device innovation.

FUJIFILM Holdings Corporation – Providing advanced EBUS imaging systems.

Medi-Globe Technologies GmbH – Offers specialized EBUS biopsy devices for thoracic diagnostics.

These players are driving technological innovation, market expansion, and global adoption of EBUS procedures.

Market Outlook

The EBUS biopsy market is poised for strong growth, driven by:

Increasing lung cancer and respiratory disease prevalence.

Rising demand for minimally invasive diagnostics that reduce patient recovery time and procedural risks.

Continuous advancements in EBUS imaging systems, scopes, and needles.

Expanding healthcare infrastructure in emerging markets, making high-quality diagnostics more accessible.

As training programs improve and equipment costs stabilize, EBUS adoption is expected to grow across hospitals, specialty clinics, and surgical centers, ensuring wider availability and improved patient outcomes globally.